In attendance:

		RSNA:
James Mulshine, MD	Ella Kazerooni, MD	Julie Lisiecki
Andrew J. Buckler, MS	Daniel Sullivan, MD	

Action items for next call (from last call – 3/27):

- Dr. Kazerooni to send ACR's more general practice guidelines to Dr. Gierada for reference
- Dr. Mulshine to follow up with Mr. Avila on bias and variability statistics
- Caveats may need to be added to the claims for data that is algorithm-dependent
- Dr. Fuld to provide parameters for optimum image quality/ starting point for:
  - Single breath hold (less than 10 seconds)
  - 16 rows or greater
  - Thin-section acquisitions
- Mr. Buckler to discuss "compliance" on next call, e.g., the spatial resolution issue across FOV
  - Mr. Buckler to work with Dr. Gierada on claims template wording offline
  - Need to harmonize claims text with appendix and compliance items

Next call: QIBA Lung Nodule Assessment in CT Screening Writing Group, *Thursday, April 24, 2014, 3 pm CT*

- Dr. Mulshine hopes to have a draft out for public comment by December 2014.

Subject: QIBA Lung Nodule Assessment in CT Screening WG: Small Nodule Profile Convergence
Sent: Thu 4/10/2014 4:12 PM

To: QIBA Lung Nodule Assessment in CT Screening Writing Group Members
Re: Small Nodule Profile Convergence

1. Sam Armato adds numbers to Dave Gierada's claim draft
2. Allocate variability to assign appropriate specs for analysis software
3. Take the compliance procedure for analysis SW from the discussion in the advanced disease profile (since it will be the same steps but just on different reference data sets)
4. Clean-up any remaining comments in document and initiate the public comment period

In parallel, the industry representatives, including at least the McNitt-Gray/Fuld email list as well as the union of the various 3A challenge participants, are encouraged to document conformance statements (aka, model-specific parameters). Industry's ability to understand the profile text and use it to craft conformance statements is the feedback we need in the public comment period.

After the public comment closes, document is revised to address the comments, and compliance testing begins.

Best regards,
Andy

Andrew J. Buckler, President and CEO
Elucid Bioimaging Inc.
225 Main Street, Suite 15 | Wenham, MA 01984 USA
Office: +1-978-468-0508
Mobile: +1-978-473-1986
Fax: +1-978-468-0527
andrew.buckler@elucidbio.com | www.elucidbio.com

Sent: Thu 4/10/2014 5:59 PM

Dear Dr. Kazerooni,

Per your request on today's *QIBA Lung Nodule Assessment in CT Screening Writing Group Update Call*, please find attached a **Word table** with all of the participants for the **QIBA CT Volumetry, QIBA Group 3A Challenges**.

Dates for these challenges were roughly as follows:
Pilot: 2011-2012
Pivotal: 2012-2013
Clinical: 2013-2014

There is some information about the challenge(s) on the QIBA wiki. Please let me know if you need anything else. I hope this is helpful.